| Liang, Li |
| Active, not recruiting | 1 | 297 | RoW | FS-1502 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Solid Tumor, Breast Cancer | 04/24 | 06/25 | | |
NCT03099850: Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies |
|
|
| Withdrawn | N/A | 999 | NA | Data Management and Monitoring | M.D. Anderson Cancer Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) | Pancreatitis | 07/21 | 07/21 | | |
| Coordinator |
NCT05070455: An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD) |
|
|
| Recruiting | 4 | 12 | US | Asceniv™ | ADMA Biologics, Inc. | Primary Immune Deficiency | 03/23 | 06/23 | | |
NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies |
|
|
| Recruiting | 3 | 143 | Europe, US | Intervention/Treatment | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 07/25 | 03/26 | | |
| Recruiting | 3 | 402 | US | Brilaroxazine, RP5063, Placebo | Reviva Pharmaceuticals | Schizophrenia | 10/24 | 10/24 | | |
STRIVE, NCT06384547: A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) |
|
|
| Recruiting | 3 | 212 | US | VRDN-001 10 mg/kg, VRDN-001 3 mg/kg | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 05/25 | 01/26 | | |
THRIVE-2, NCT06021054: A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED) |
|
|
| Recruiting | 3 | 159 | Europe, US, RoW | VRDN-001 10 mg/kg Drug: | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 12/24 | 09/25 | | |
NCT06107686: A Study of YL202 in Selected Patients With Advanced Solid Tumors |
|
|
| Active, not recruiting | 2 | 200 | RoW | YL202 should be intravenously infused | MediLink Therapeutics (Suzhou) Co., Ltd. | NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors | 11/26 | 11/28 | | |
NCT06057922: A Study YL201 in Patients With Selected Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 640 | RoW | YL201 for Injection | MediLink Therapeutics (Suzhou) Co., Ltd. | Advanced Solid Tumor | 10/26 | 10/27 | | |
NCT06186596: Self-Administered Intralesional Injections for Acne |
|
|
| Recruiting | N/A | 150 | US | Triamcinolone delivered via injection assistance device | ACOM Labs | Acne Vulgaris | 01/24 | 01/24 | | |
NCT05879198: Train Your Brain: A Pilot Project to Improve Memory and Decision Making |
|
|
| Enrolling by invitation | N/A | 23 | US | Computer-based Intervention | Henry Ford Health System, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) | Behavior, Health | 06/24 | 06/24 | | |
PRIMA-102, NCT05936970: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD |
|
|
| Recruiting | N/A | 830 | US | | Aqtual, Inc. | Rheumatoid Arthritis | 03/25 | 09/25 | | |
NCT04642898: Increasing Treatment Efficacy Using SMART Methods for Personalizing Care |
|
|
| Active, not recruiting | N/A | 66 | US | Standard UP Treatment, Capitalization UP Treatment, Compensation UP Treatment | Shannon E. Sauer-Zavala, National Institute of Mental Health (NIMH) | Anxiety Disorders, Post Traumatic Stress Disorder, Obsessive-Compulsive Disorder | 06/24 | 06/24 | | |
NCT03594994: Metabolic Effects of Sleep Extension in People With Obesity |
|
|
| Recruiting | N/A | 40 | US | Sleep extension | Washington University School of Medicine | Insulin Resistance, Obesity | 05/24 | 06/24 | | |
NCT04587518: Five Factor Model Treatment for Borderline Personality Disorder |
|
|
| Active, not recruiting | N/A | 40 | US | Personality-Based Cognitive Behavioral Therapy | Shannon E. Sauer-Zavala | Borderline Personality Disorder | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 1017 | US | Impella 5.5 | Abiomed Inc. | Cardiogenic Shock, Acute Decompensated Heart Failure | 12/24 | 12/24 | | |
NCT03701828: Liver Health and Metabolic Function in People With Obesity |
|
|
| Enrolling by invitation | N/A | 30 | US | Weight loss surgery, Sleeve gastrectomy, Roux-en-Y, biliopancreatic diversion | Washington University School of Medicine | Non-Alcoholic Fatty Liver Disease | 11/24 | 11/24 | | |
| Recruiting | N/A | 87 | US | Telemedicine | University of Pennsylvania | Psoriatic Arthritis | 02/25 | 02/25 | | |
| Recruiting | N/A | 200 | Europe | Modified prolonged exposure, Brief intervention, cognitive behavioral therapy | St. Olavs Hospital, Norwegian University of Science and Technology, The Research Council of Norway, Norwegian Women's Public Health Association (Norske Kvinners Sanitetsforening), National Centre for Emergency Primary Health Care, NORCE, UiT The Arctic University of Norway | Post Traumatic Stress Disorder, Rape Sexual Assault, Sexual Dysfunctions, Psychological, Pelvic Floor Myalgia, Pelvic Pain Syndrome, Depression, Anxiety, Sleep Disturbance, Activity, Motor, Cortisol Deficiency | 05/25 | 12/27 | | |
| Recruiting | N/A | 506 | US | CHOICES, eBook | University of Florida, National Human Genome Research Institute (NHGRI) | Sickle Cell Disease, Sickle Cell Trait | 06/25 | 06/25 | | |
| Active, not recruiting | N/A | 220 | US | EXTEND Plus, EXTEND | Duke University, National Institute of Nursing Research (NINR) | Diabetes Mellitus, Type 2, Hypertension | 07/25 | 07/25 | | |
| Zhong, Zhixiong |
NCT06471218: Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia |
|
|
| Not yet recruiting | 2 | 42 | RoW | SHR-1918; SHR-1918 Placebo | Beijing Suncadia Pharmaceuticals Co., Ltd | Hyperlipidemia | 04/25 | 06/25 | | |
SIBLINT ISR, NCT04240444: Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis |
|
|
| Completed | N/A | 260 | RoW | drug-coated balloon Catheter | B. Braun Medical International Trading Company Ltd., CCRF Inc., Beijing, China | Coronary Artery Disease, In Stent Restenosis | 07/22 | 08/22 | | |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
NCT05774288: Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders. |
|
|
| Recruiting | N/A | 244 | RoW | Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders | Lifetech Scientific (Shenzhen) Co., Ltd. | Patent Foramen Ovale, Cryptogenic Stroke | 04/25 | 06/29 | | |
NCT06024525: Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters Swide® |
|
|
| Not yet recruiting | N/A | 236 | RoW | Paclitaxel-Coated Coronary Balloon Catheters, Paclitaxel-Releasing Coronary Balloon Catheters | Shanghai Shenqi Medical Technology Co., Ltd | Coronary Artery Disease | 06/25 | 06/26 | | |
| Zuguang, Zuguang |
NCT04370925: Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis |
|
|
| Recruiting | 3 | 688 | RoW | Radical colectomy, HIPEC, Systemic chemotherapy | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Nanfang Hospital of Southern Medical University, Sun Yat-sen University, Sixth Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, Meizhou People's Hospital, First People's Hospital of Foshan, Shantou Central Hospital, Jiangmen Central Hospital, Shenzhen Second People's Hospital, Zhongshan People's Hospital, Guangdong, China, ZhuHai Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Hospital, Beijing Cancer Hospital, Peking University People's Hospital, Fudan University, The Second Affiliated Hospital of Chongqing Medical University, Chongqing University Cancer Hospital, First Affiliated Hospital of Chongqing Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Wuhan University, Sichuan Provincial People's Hospital, West China Hospital, The People's Hospital of Leshan, People’s Hospital of Deyang City, Hebei Medical University Fourth Hospital, The First Affiliated Hospital of Nanchang University, The Affiliated Hospital Of Southwest Medical University, The Affiliated Hospital of Xuzhou Medical University, People's Hospital of Guangxi, The Third People's Hospital of Chengdu, The Affiliated Tumor Hospital of Guangxi Medical University | Colorectal Cancer | 04/24 | 04/26 | | |
| Zeng, Haijing |
NCT04370925: Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis |
|
|
| Recruiting | 3 | 688 | RoW | Radical colectomy, HIPEC, Systemic chemotherapy | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Nanfang Hospital of Southern Medical University, Sun Yat-sen University, Sixth Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, Meizhou People's Hospital, First People's Hospital of Foshan, Shantou Central Hospital, Jiangmen Central Hospital, Shenzhen Second People's Hospital, Zhongshan People's Hospital, Guangdong, China, ZhuHai Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Hospital, Beijing Cancer Hospital, Peking University People's Hospital, Fudan University, The Second Affiliated Hospital of Chongqing Medical University, Chongqing University Cancer Hospital, First Affiliated Hospital of Chongqing Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Wuhan University, Sichuan Provincial People's Hospital, West China Hospital, The People's Hospital of Leshan, People’s Hospital of Deyang City, Hebei Medical University Fourth Hospital, The First Affiliated Hospital of Nanchang University, The Affiliated Hospital Of Southwest Medical University, The Affiliated Hospital of Xuzhou Medical University, People's Hospital of Guangxi, The Third People's Hospital of Chengdu, The Affiliated Tumor Hospital of Guangxi Medical University | Colorectal Cancer | 04/24 | 04/26 | | |
| Li, Liang |
NCT04421495: Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China |
|
|
| Active, not recruiting | 4 | 608 | RoW | Delamanid, anti-TB new drug containing regimen | Beijing Chest Hospital | Multidrug Resistant Tuberculosis | 06/22 | 07/24 | | |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
| Recruiting | 3 | 270 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 10/23 | 01/24 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
|
|
| Withdrawn | 2 | 177 | RoW | Balstilimab, Balstilimab + Zalifrelimab | Agenus Inc., Betta Pharmaceuticals Co., Ltd. | Cervical Cancer | 12/24 | 12/24 | | |
| Wu, Guowu |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT05716087: A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 62 | RoW | LP-168, NWP-775 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 02/24 | 12/25 | | |
NCT05284994: TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 160 | RoW | TQ-B3525 Tablets, Osimertinib Mesylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Nonsmall-cell Lung Cancer | 04/24 | 06/24 | | |
| Xu, Qingdong |
NCT04381143: ASPIrin in Reducing Events in Dialysis ( ASPIRED ) |
|
|
| Recruiting | 4 | 9000 | RoW | Aspirin 100 mg Oral Tablet, Matching Placebo | Guangdong Provincial People's Hospital, The George Institute | CKD (Chronic Kidney Disease) Stage 5D | 09/26 | 12/26 | | |
| Wei, Tongguo |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
| Zhu, Xinghua |
NCT04381143: ASPIrin in Reducing Events in Dialysis ( ASPIRED ) |
|
|
| Recruiting | 4 | 9000 | RoW | Aspirin 100 mg Oral Tablet, Matching Placebo | Guangdong Provincial People's Hospital, The George Institute | CKD (Chronic Kidney Disease) Stage 5D | 09/26 | 12/26 | | |
| Huang, Xiwen |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
NCT06010901: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. |
|
|
| Recruiting | 1 | 75 | RoW | TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Colorectal Cancer | 03/25 | 07/25 | | |
| Wu, Jingna |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
| Recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 10/24 | 06/27 | | |
